North Carolina is currently home to 2623 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Recruiting
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: The Center for Neuropsychiatry and Brain Stimulation (CNBS) ARC Health, Cary, North Carolina
Conditions: Treatment Resistant Depression
Register for Updates
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT02847559
Recruiting
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Vidant Medical Center, East Caroling University, Greenville, North Carolina
Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Register for Updates
Graded Exposure and Mindfulness Meditation for Patients Post-ACL Reconstruction
NCT05949177
Recruiting
To evaluate the effect of graded exposure and mindfulness meditation after ACLR, the investigators will determine the effect of graded exposure and mindfulness meditation to 1) decrease self-reported injury-related fear and reinjury anxiety, and 2) improve lower extremity reaction time when compared to a waitlist control group.
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
12/04/2024
Locations: Woollen Gymnasium, 300 South Road, Chapel Hill, North Carolina
Conditions: Anterior Cruciate Ligament Injuries
Register for Updates
Improving Providers' Decision-Making and Reducing Information Overload Using Information Visualization in EHRs
NCT05937646
Recruiting
This study aims to test the efficacy of an information visualization dashboard on decision-making using a randomized controlled trial with crossover. This study aims to test the efficacy of using an information visualization dashboard on ICU providers' decision-making, efficiency, and performance compared to their institutional EHR through a randomized control trial with crossover.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/04/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Electronic Health Records, Usability, Information Seeking Behavior, Critical Care
Register for Updates
Safety and Effectiveness of the Yaari Extractor for Management of Shoulder Dystocia
NCT05913609
Recruiting
Prospective, multi-center, single arm with historical control, to verify the safety and effectiveness of the Yaari Extractor used by board certified or board eligible U.S. OB/GYN physicians in the management of shoulder dystocia.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Unified Women's Clinical Research, Winston-Salem, North Carolina
Conditions: Shoulder Dystocia
Register for Updates
Depression, Aging, Stress and Heart Health Study
NCT05570721
Recruiting
Depression is a known risk factor for cardiovascular disease (CVD), and this comorbidity contributes significantly to the morbidity and mortality of women. The menopausal transition or perimenopause is a period of vulnerability for both depression and CVD, making it a key time to study this critical public health issue. This research will preliminarily explore whether disruption in two novel stress pathways 1) the renin-angiotensin-aldosterone system (RAAS) and autonomic nervous system (ANS) and... Read More
Gender:
FEMALE
Ages:
Between 44 years and 55 years
Trial Updated:
12/04/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Menopause, Depression, Heart Disease in Women, Stress
Register for Updates
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT05476770
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
12/04/2024
Locations: Carolina-Levine Children's Hospital, Charlotte, North Carolina
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Register for Updates
REMASTer: REcurrent Brain Metastases After SRS Trial
NCT05124912
Recruiting
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
Register for Updates
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Recruiting
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: UNC- Chapel Hill, Chapel Hill, North Carolina
Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Register for Updates
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
NCT02704858
Recruiting
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase 1 is a standard cohort dose escalation 3+3 design used to determine the maximum tolerated dose for Phase 2a. There will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Glioblastoma Multiforme
Register for Updates
Daoist Zhanzhuang and Human Flourishing
NCT06573034
Recruiting
This project investigates the impact of Daoist Zhanzhuang (sometimes spelled as Chan Chuang) on human flourishing, and explores the physiological, psychological, and spiritual mechanisms. This study will be a two-arm randomized controlled trial, with mixed-methods and repeated-measures assessment of outcome variables. The two arms will include an active control condition (i.e., sham wall squat) and the Daoist Zhanzhuang condition. Outcome variables will include physiological measures of heart ra... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
12/03/2024
Locations: University of North Carolina at Charlotte, Charlotte, North Carolina
Conditions: Stress, Physiological, Stress, Psychological, Inflammatory Response, Well-Being, Psychological
Register for Updates